27. The use of any of claims 11-24, wherein the antibody molecule is administered after known exposure to the influenza virus infection.

28. The use of any of claims 11-24, wherein the antibody molecule is administered after manifestation of an effect or a symptom of the influenza virus infection.

29. The use of any of claims 11-28, wherein the human subject is tested for the influenza virus.

~~30. The use of any of claims 11-29 for the manufacture of a medicament for preventing the influenza virus infection in the human subject.~~

~~31. The use of any of claims 11-29 for the manufacture of a medicament for treating the influenza virus infection in the human subject.~~

~~32~~30. A pharmaceutical composition comprising the antibody molecule of any of claims 1-10 and a pharmaceutically acceptable carrier.

~~33~~31. A kit comprising the antibody molecule of any of claims 1-10; and a pharmaceutically acceptable delivery vehicle or buffer, a delivery device, or both.